Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
PARIS, Oct 24, 2011 (BUSINESS WIRE) -- Sanofi announced today the appointment of David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1, 2011. He will report to Christopher A. Viehbacher, Chief Executive Officer of Sanofi, and will join the Group Management Committee. Christopher A. Viehbacher will retain the position of Chairman, Genzyme.
"After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme," said Christopher A. Viehbacher, Chief Executive Officer of Sanofi. "David's commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group. His combination of medical and business experience will be essential to move Genzyme's broad portfolio of products forward and deliver much-needed therapies to patients."
Under David Meeker's leadership, Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise. Previous Genzyme divisions - Renal, Biosurgery and Oncology - have been integrated within the existing Sanofi portfolio giving them greater global scale and capabilities.
David joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Over the years he has held key positions of increasing responsibility as he led the development of treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme(R), Fabrazyme(R) and Myozyme(R). In 2009, he was promoted to Chief Operating Officer of Genzyme and has played an important role in the integration since April of this year. David received his M.D. from the University of Vermont Medical School, and completed the Advanced Management Program at Harvard Business School in 2000.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris FR:SAN -0.87% and in New York SNY +2.19% .
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50039969&lang=en
SOURCE: Genzyme
Sanofi
Media Relations
Jean-Marc Podvin, +33-1-53-77-46-46
[email protected]
or
Investor Relations
Sebastien Martel, +33-1-53-77-45-45
[email protected]
or
Genzyme Media Relations
Bo Piela, +1-617-768-6579
[email protected]
Copyright Business Wire 2011